Joseph L. Kim

6.2k citations

21 papers · 3.9k indexed · 4 hit papers · h-index 14

Molecular Biology top 2%
Oncology top 5%
Hepatology top 2%
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 5%

Co-authors: S.K. Burley Dimitar B. Nikolov Christoph Lengauer Nicolas Stransky Stefanie S. Schalm Ethan Cerami Chao Lin Kurt Morgenstern
Topics: Melanoma and MAPK Pathways (4 papers)Protein Kinase Regulation and GTPase Signaling (4 papers)Hepatitis C virus research (4 papers)
Cited by: Hepatology Molecular Biology Oncology
Journals: Nature Cell Nature Communications
Partner nations: United States South Korea China

In The Last Decade

Joseph L. Kim

21 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Co-crystal structure of TBP recognizing the minor groove of a TATA element

1993 901 citations Joseph L. Kim, Dimitar B. Nikolov et al. Nature profile →
X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex

1995 698 citations Joseph L. Kim, Kathy Hsiao et al. Cell profile →
The landscape of kinase fusions in cancer

2014 657 citations Nicolas Stransky, Ethan Cerami et al. Nature Communications profile →
Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

1998 518 citations Joseph L. Kim, Kurt Morgenstern et al. Structure profile →

Peers

Countries citing papers authored by Joseph L. Kim

Since Specialization

Citations

This map shows the geographic impact of Joseph L. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph L. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph L. Kim more than expected).

Fields of papers citing papers by Joseph L. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph L. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph L. Kim. The network helps show where Joseph L. Kim may publish in the future.

Co-authorship network of co-authors of Joseph L. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph L. Kim. A scholar is included among the top collaborators of Joseph L. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph L. Kim. Joseph L. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma 2019 ·Cancer Discovery ·Megan Hatlen,Oleg Schmidt-Kittler,Cori Ann Sherwin,(unknown),Nooreen Rubin,Michael P. Sheets,Joseph L. Kim,(unknown),Neil Bifulco,Natasja Brooijmans,Hongliang Shi,Timothy J. Guzi,Andy Boral,Christoph Lengauer,Marion Dorsch,Richard D. Kim,Yoon‐Koo Kang,Beni B. Wolf,Klaus P. Hoeflich	90
2	Targeting kinases with precision 2018 ·Molecular & Cellular Oncology ·Alexandra K. Gardino,Erica N Evans,Joseph L. Kim,Natasja Brooijmans,Brian L. Hodous,Beni B. Wolf,Christoph Lengauer	12
3	Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling 2016 ·Bioorganic & Medicinal Chemistry ·Longbin Liu,Matthew R. Lee,Joseph L. Kim,Douglas A. Whittington,Howard Bregman,Zihao Hua,Richard T. Lewis,Matthew W. Martin,Nobuko Nishimura,Michele Potashman,Kevin Yang,(unknown),(unknown),Linda F. Epstein,Carol Babij,Manory Fernando,Josette Carnahan,Mark H. Norman	13
4	Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors 2016 ·Cancer Research ·Rami Rahal,Erica N Evans,Wei Hu,Michelle Maynard,Paul Fleming,Lucian DiPietro,Joseph L. Kim,Michael P. Sheets,(unknown),Kevin Wilson,Nicolas Stransky,Jason D. Brubaker,Timothy J. Guzi,Nancy E. Kohl,Christoph Lengauer	10
5	First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway 2015 ·Cancer Discovery ·Margit Hagel,Chandra Miduturu,Michael P. Sheets,Nooreen Rubin,Weifan Weng,Nicolas Stransky,Neil Bifulco,Joseph L. Kim,Brian L. Hodous,Natasja Brooijmans,Adam Shutes,Christopher Winter,Christoph Lengauer,Nancy E. Kohl,Timothy J. Guzi	247
6	Abstract 954: The landscape of kinase fusions in cancer 2015 ·Cancer Research ·Nicolas Stransky,Ethan Cerami,Stefanie S. Schalm,Joseph L. Kim,Klaus P. Hoeflich,Christoph Lengauer	1
7	Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants 2015 ·Cancer Research ·Erica N Evans,Brian L. Hodous,Alexandra K. Gardino,Alison Davis,Julia Zhu,Adam Shutes,Joseph L. Kim,Kevin Wilson,(unknown),Yulian Zhang,(unknown),Nancy E. Kohl,Vivek J. Kadambi,Timothy J. Guzi,Christoph Lengauer	18
8	The landscape of kinase fusions in cancerbreakdown → 2014 ·Nature Communications ·Nicolas Stransky,Ethan Cerami,Stefanie S. Schalm,Joseph L. Kim,Christoph Lengauer	657
9	Abstract 1975: Discovery of a potent and selective Jak2 inhibitor that suppresses GM-CSF-induced STAT5 phosphorylation and Erythropoietin-induced reticulocytosis in vivo 2011 ·Cancer Research ·Liqin Liu,Gordon Moody,Jeanne Pistillo,Renee Emkey,Violeta Yu,Elizabeth M. Doherty,Xin Huang,Joseph L. Kim,Angus M. Sinclair	1
10	Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth 2010 ·Molecular Cancer Therapeutics ·Josette Carnahan,Pedro J. Beltran,Carol Babij,Quynh‐Thu Le,Mark J. Rose,Steven Vonderfecht,Joseph L. Kim,Adrian L. Smith,Karthik Nagapudi,Martin A. Broome,Manory Fernando,Hue T. Kha,Brian Belmontes,Robert Radinsky,Richard Kendall,Teresa L. Burgess	58
11	Abstract 21: Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells 2010 ·Cancer Research ·Josette Carnahan,Pedro J. Beltran,Carol Babij,Quynh‐Thu Le,Mark J. Rose,Steven Vonderfecht,Joseph L. Kim,Adrian L. Smith,Martin A. Broome,Manory Fernando,Hue T. Kha,Brian Belmontes,Robert Radinsky,Richard Kendall,Teresa L. Burgess	2
12	Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline 2009 ·Journal of Medicinal Chemistry ·Adrian L. Smith,(unknown),Nick A. Paras,Qi Huang,(unknown),Elizabeth M. Doherty,Thomas Nixey,Joseph L. Kim,Douglas A. Whittington,Linda F. Epstein,Matthew R. Lee,Mark J. Rose,Carol Babij,Manory Fernando,Kristen L. Hess,Quynh‐Thu Le,Pedro J. Beltran,Josette Carnahan	90
13	Inhibitors of hepatitis C virus NS3·4A protease 1. Non-Charged tetrapeptide variants 2003 ·Bioorganic & Medicinal Chemistry Letters ·Robert B. Perni,(unknown),(unknown),Lawrence F. Courtney,David D. Deininger,Luc J. Farmer,Cynthia A. Gates,Scott L. Harbeson,Joseph L. Kim,James A. Landro,Rhonda B. Levin,Yu-Ping Luong,(unknown),J. PITLIK,B. Govinda Rao,(unknown),John A. Thomson,Roger D. Tung,John H. Van Drie,Yunyi Wei	25
14	Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors 1999 ·Structure ·Xiaotian Zhu,Joseph L. Kim,John Newcomb,Paul Rose,David R. Stover,Leticia M. Toledo,Huilin Zhao,Kurt Morgenstern	205
15	Structure-Based Mutagenesis Study of Hepatitis C Virus NS3 Helicase 1999 ·Journal of Virology ·Chao Lin,Joseph L. Kim	81
16	Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwindingbreakdown → 1998 ·Structure ·Joseph L. Kim,Kurt Morgenstern,(unknown),(unknown),(unknown),Mark A. Murcko,Chao Lin,Paul R. Caron	518
17	Hepatitis C virus NS3/4A protease 1998 ·Antiviral Research ·Ann D. Kwong,Joseph L. Kim,(unknown),Daša Lipovšek,Scott A. Raybuck	102
18	X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complexbreakdown → 1995 ·Cell ·(unknown),Joseph L. Kim,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Kathy Hsiao,(unknown)	698
19	1.9 Å resolution refined structure of TBP recognizing the minor groove of TATAAAAG 1994 ·Nature Structural & Molecular Biology ·Joseph L. Kim,S.K. Burley	184
20	Co-crystal structure of TBP recognizing the minor groove of a TATA elementbreakdown → 1993 ·Nature ·Joseph L. Kim,Dimitar B. Nikolov,S.K. Burley	901

About Joseph L. Kim

Joseph L. Kim is a scholar working on Hepatology, Oncology and Virology, having authored 21 papers that have together received 3.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Hepatitis C virus research (4 papers). The work is most often cited by research in Hepatology (416 citations), Molecular Biology (2.9k citations) and Oncology (697 citations). Joseph L. Kim has collaborated with scholars based in United States, South Korea and China. Frequent co-authors include S.K. Burley, Dimitar B. Nikolov, Christoph Lengauer, Nicolas Stransky, Stefanie S. Schalm, Ethan Cerami, Chao Lin, Kurt Morgenstern, Kathy Hsiao and Mark A. Murcko. Their work appears in journals such as Nature, Cell and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact